China FDA admits limits but solutions sketchy
This article was originally published in Scrip
Drug companies in China have long been frustrated by lengthy processes to get new drugs approved and registered in the country, but such complaints appear to have been taken on board by the China Food and Drug Administration (CFDA) if new proposals are anything to go by.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.